Residual neuromuscular block: lessons unlearned. Part II: methods to reduce the risk of residual weakness.
about
Qualitative Neuromuscular Monitoring: How to Optimize the Use of a Peripheral Nerve Stimulator to Reduce the Risk of Residual Neuromuscular BlockadeUse of neuromuscular blockers and neostigmine for general anesthesia and its association with neuraxial blockade: A retrospective studyComparison of neostigmine induced reversal of vecuronium in normal weight, overweight and obese female patientsObservational study on patterns of neuromuscular blockade reversalSugammadex for reversal of neuromuscular blockade: a retrospective analysis of clinical outcomes and cost-effectiveness in a single center.Train-of-four and tetanic fade are not always a prejunctional phenomenon as evaluated by toxins having highly specific pre- and postjunctional actions.Sepsis Strengthens Antagonistic Actions of Neostigmine on Rocuronium in a Rat Model of Cecal Ligation and PunctureThe use of sugammadex for bariatric surgery: analysis of recovery time from neuromuscular blockade and possible economic impactEnhanced Recovery After Surgery (ERAS) for gastrointestinal surgery, part 2: consensus statement for anaesthesia practice.Clinical assessment and train-of-four measurements in critically ill patients treated with recommended doses of cisatracurium or atracurium for neuromuscular blockade: a prospective descriptive study.Reversal agents in anaesthesia and critical care.The efficacy and safety of sugammadex for reversing postoperative residual neuromuscular blockade in pediatric patients: A systematic review.Postoperative residual block in postanesthesia care unit more than two hours after the administration of a single intubating dose of atracurium.Introduction of sugammadex as standard reversal agent: Impact on the incidence of residual neuromuscular blockade and postoperative patient outcome.Neuromuscular monitoring, muscle relaxant use, and reversal at a tertiary teaching hospital 2.5 years after introduction of sugammadex: changes in opinions and clinical practice.Neuromuscular transmission monitoring: Beyond the electric shocks and the shaking hands.Delayed Recovery from Anaesthesia: Missing Information.Preparing for the unexpected: special considerations and complications after sugammadex administrationComparative pharmacodynamics of pancuronium, cisatracurium, and CW002 in rabbits.In response: Interdisciplinary intraoperative communication and collaboration needed for optimal neuromuscular blockade management.Reversal of experimental paralysis in a human by intranasal neostigmine aerosol suggests a novel approach to the early treatment of neurotoxic envenomation.Improving Neuromuscular Monitoring and Reducing Residual Neuromuscular Blockade With E-Learning: Protocol for the Multicenter Interrupted Time Series INVERT Study.The comparative efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. A Cochrane systematic review with meta-analysis and trial sequential analysis.Neuromuscular Block and Blocking Agents in 2018.
P2860
Q26741519-EB3857E8-ED58-4287-B7BA-160D6104A453Q33879788-C1CD8F36-CE26-4971-961D-678218A468FEQ35228475-5EB2587F-3FBF-4422-AA5C-D443E1499B11Q36172044-597070AF-E086-45C8-91D7-11D7EB21CCAFQ36603957-161B6CF1-21DA-4CF8-97E5-896A290F3DDCQ36788088-A6C6CEE5-C650-43C8-A32A-C3285A42A2D7Q37011371-00A56B50-F49C-426C-BA86-E777D46DA368Q37069177-285FE63F-8D87-4DE4-BEED-C4EF098FDABBQ37334030-59BBC974-06A2-4A7C-A632-835B234933AEQ37594897-D88E0FD0-8D9C-4516-9B1D-8A1107B95E43Q38661905-1C433DD2-4398-46F8-B109-E6872A1679F8Q38673159-3641CF92-732B-459C-A5D2-BC02175E1B65Q39050598-D023F5E1-12E7-4F30-9040-2B5ADBFF55C5Q40838495-5ACCC9D5-1F3C-4E9C-80D0-25419C416914Q41455793-F5F70032-ADCF-4326-AD90-E4D4FAA12853Q41844263-58BF3120-3CE4-4919-B6DB-AC319901BD35Q42363932-B124EB93-5962-4C6E-802A-B41E30BE06F3Q42682587-02A9421F-BD80-4F96-91B9-21BC5EE92CDFQ42782085-03F992AE-1DED-4AE7-94AD-02FCD70BD949Q42857985-6E77577C-66A3-4B28-B165-028333426D50Q42927944-EBF772E6-79A8-4096-A2D4-FBB602E9FD91Q45549397-BE051A14-39B0-4C26-B1E2-892290F75105Q47217370-CA07BFA4-D074-4B5E-B7A8-EA43D3448057Q55215771-011E2D4C-0C05-484E-B4CC-597CBD5CFCF7
P2860
Residual neuromuscular block: lessons unlearned. Part II: methods to reduce the risk of residual weakness.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Residual neuromuscular block: ...... the risk of residual weakness.
@ast
Residual neuromuscular block: ...... the risk of residual weakness.
@en
Residual neuromuscular block: ...... the risk of residual weakness.
@nl
type
label
Residual neuromuscular block: ...... the risk of residual weakness.
@ast
Residual neuromuscular block: ...... the risk of residual weakness.
@en
Residual neuromuscular block: ...... the risk of residual weakness.
@nl
prefLabel
Residual neuromuscular block: ...... the risk of residual weakness.
@ast
Residual neuromuscular block: ...... the risk of residual weakness.
@en
Residual neuromuscular block: ...... the risk of residual weakness.
@nl
P1476
Residual neuromuscular block: ...... the risk of residual weakness
@en
P2093
Glenn S Murphy
P304
P356
10.1213/ANE.0B013E3181DA8312
P407
P577
2010-05-04T00:00:00Z